China Drug Discovery Landscape
Interview with Helen Chen, Ph.D., Director and Partner, Head of China Life Sciences, L.E.K. Consulting, Shanghai
Part 1: China or not? The decision process
287 views
00:11:32 - Uploaded by Essinova on June 16, 2010
"... it seems that every other week there is a new announcement of a Big Pharma R&D center expansion, another CRO getting funding, or a domestic Chinese company planning a U.S. clinical trial." In this interview at BioPacific 2010, where she presented an overview of the China drug discovery landscape, Helen Chen discussed the changing dynamics of China R&D, and shared some key learning as an active participant in the arena advising Western and Chinese domestic clients.
Tags: CABS, BioPacific 2010, Helen Chen, LEK, China, CRO, pre-clinical, profiling
RELATED
COMMENTS
There are 0 comments. You must be logged in to comment.
Discovery & Development
-
Changing Landscape of Global BioPharmaceutical Innovation and Collaboration
-
Emerging Trends and Opportunities in the BioPharmaceutical Industry in China and the US
-
Balancing Aggressiveness and Conservatism
-
US-China Anti-Cancer Association Scholar Award for Cancer Research
-
Expanding Access to Patients in Need Around the World
-
BioPacific 2010 - Drug Discovery and Development in Changing Times
-
China Drug Discovery Landscape
-
China Drug Discovery Landscape
-
Optivia Webinar - Transporter-Enzyme and Transporter-Transporter Interplay in Predicting Drug Absorption and Disposition
-
Location Determines PKC Specificity
-
KAI Selective PKC Inhibitors
-
KAI Selective PKC Activators
-
Epitomics Inc.
